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Read-throughMutations in the fukutin-related protein (FKRP) gene cause limb-girdle muscular dystrophy type 2I
(LGMD2I) as well as other severe muscle disorders, including Walker–Warburg syndrome, muscle–eye–
brain disease, and congenital muscular dystrophy type 1C. The FKRP gene encodes a putative
glycosyltransferase, but its precise localization and functions have yet to be determined. In the present
study, we demonstrated that normal FKRP is secreted into culture medium and mutations alter the pattern of
secretion in CHO cells. L276I mutation associated with mild disease phenotype was shown to reduce the
level of secretion whereas P448L and C318Y mutations associated with severe disease phenotype almost
abolished the secretion. However, a truncated FKRP mutant protein lacking the entire C-terminal 185 amino
acids due to the E310X nonsense mutation was able to secrete as efﬁciently as the normal FKRP. The N-
terminal signal peptide sequence is apparently cleaved from the secreted FKRP proteins. Alteration of the
secretion pathway by different mutations and spontaneous read-through of nonsense mutation may
contribute to wide variations in phenotypes associated with FKRP-related diseases.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Recently, mutations in several genes have been associated with a
sub-set of muscular dystrophies that share a common secondary
abnormality in O-linked glycosylation of α-dystroglycan (α-DG),
collectively known as dystroglycanopathies [1,2]. These genes include
fukutin, fukutin-related protein (FKRP), LARGE, POMGnT1, POMT1, and
POMT2 encoding known or putative glycosyltransferases [3-8].
Among the genes of particular interest is FKRP. Mutations in the
FKRP gene cause a broad spectrum of phenotypes ranging from limb-
girdle muscular dystrophy type 2I (LGMD2I) with mild clinical
symptoms [4] to more severe congenital muscular dystrophy type
1C (MDC1C) [5,9]. In addition, affected patients frequently develop
cardiomyopathy [10]. FKRP also plays an important role in other non-
muscle tissues. For example, FKRP mutations were reported in
patients diagnosed with muscle–eye–brain disease (MEB) and
Walker–Warburg syndrome (WWS), both of which are associated
with severe brain defects and mental retardation in addition to
muscle involvement [11-12]. Mechanism(s) underlying the wide
phenotypic variations is not understood. The most noticeable
molecular pathology of FKRP-related diseases is the secondary defects
in glycosylation of α-DG as revealed by the reduction or loss of
immunoreactivity to the IIH6 and VIA4 antibodies, which recognizeu).
ll rights reserved.the sugar moiety of the protein [1,2]. This leads to the assumption that
FKRP may function as a glycosyltransferase. This hypothesis is
supported by sequence analysis showing that FKRP contains a
consensus putative catalytic DxD motif commonly found in many
glycosyltransferases in the Golgi apparatus [13-14]. However, there is
no direct evidence indicating that FKRP is a glycosyltransferase.
Previous sequence analysis predicts that FKRP is a type II single-
pass transmembrane protein which anchors to the membrane and
targets to the Golgi apparatus [13]. It has been known that
transmembrane domains of a protein share common structural
features with signal peptides. Sequence analysis with a program for
protein structure/function prediction (Phobius prediction; phobias.
cbr.su.se/cgi-bin/predict.pl) suggests that the transmembrane do-
main of FKRP is a signal peptide with the likelihood of the protein to
be secreted. In agreement with the prediction, fukutin, another
putative glycosyltransferase and sharing high sequence homologue
with FKRP, was shown to be secreted into culture media [3]. However,
the functional signiﬁcance of the secreted fukutin is not clear.
Modiﬁcations of glycosyltransferases, such as formation of dimers
and proteolytic cleavage and secretion as a soluble form, are
considered potentially important processes to regulate the activity
of glycosyltransferases [15-17]. For example, β 1,6-N-acetylglucosa-
minyltransferase V (GnT-V) secreted from human colon carcinoma
cells is directly involved in tumor angiogenesis in a glycosylation-
independent manner [18], suggesting that secreted glycosyltransfer-
ase could have distinctive function. In this study, we investigated
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mutations on the secretory pathway. We showed that both normal
human and mouse FKRPs were secreted into the culture medium
efﬁciently in CHO cells and mutations affected the secretion.
Interestingly, spontaneous read-through was clearly detected for
the E310X nonsense mutant, resulting in low level expression of full-
length FKRP. Our results suggest that alteration of the secretory
pathway by individual mutation may add another layer of complexity
to the variation of phenotypes associated with FKRP-related diseases
although potential biological functions of the secreted FKRP protein
remain to be explored.
2. Materials and methods
2.1. Construction of expression plasmids
Full-length coding sequence of the human FKRP was ampliﬁed by
RT-PCR from the total RNA isolated from a normal skeletal muscle. The
cDNA was placed at the 5′ end of the eGFP coding sequence in the
pEGFP-N3 vector (Clontech). The subsequent removal of the GFP tag
from the construct generated an untagged human FKRP expression
vector. The human L276I and P488L mutant constructs were created
by PCR-directed mutagenesis as described previously [19]. Same
approach was used for generating the E310X FKRP construct with the
following pair of primers; hfkrp-310/MS1-F1202-1222, 5′-C TAC CTC
TAC TAG GAG CGC T-3′ and hfkrp-310/MR1-R1222-1202, 5′-A GCG
CTC CTA GTA GAG GTA G-3′ (mutated nucleotide is in bold and
underlined). The kozak sequence upstream of the GFPwas removed to
reduce background GFP level for read-through study. The expression
constructs of mouse normal FKRP, L276I, C318Y and P448L mutants
were tagged with eYFP as reported previously (13).
2.2. Cell culture and transfection
CHO cells (2×105/well of 6-well plates) were grown in RPMI-
1640 medium supplemented with 10% FBS, and 4 mM L-glutamine.
Twenty-four hours after plating, cells were transfected with 5 μg of
each construct using Lipofectamine 2000 as per manufacturer's
instructions. After 24 h, the cells were then grown in 2 ml of
Optipro SFM, 12309 (Invitrogen, Carlsbad, CA) supplemented
with 4 mM L-glutamine for 48 h in 5% CO2. The culture media were
collected and pre-cleared by centrifugation at 13,000 rpm for 15 min.
The supernatant was subsequently concentrated from the original
volume (2 ml) to a smaller volume (250 μl) using concentrator
VIVASPIN, 10,000MWCO, (VIVASCIENCE, Massachusetts) according to
manufacturer's instructions. The cells were collected separately by
scrapping off from the culture plate and referred to as cell pellet. At
least three independent transfections were performed to conﬁrm the
results. Transfected cells were also selected with G418 at the
concentration of 1.5 mg/ml and maintained as cell lines with stable
expression of FKRPs. All culture media and transfection reagents were
purchased from Invitrogen/Gibco Life Sciences.
2.3. Antibodies and immunohistochemistry
FKRP-5643 (FKRP-STEM) rabbit polyclonal antibody against the
stem region (amino acid residues 29–130) of the mouse FKRP was
used as described previously [14]. The anti-GM130 monoclonal
antibody was purchased from BD Biosciences (San Jose, CA).
Monoclonal antibody against β-actin (clone AC-74, A 5316) and
antibody against GFP/YFP (clone JL-8) were obtained from Sigma and
Clontech respectively.
Cells were ﬁxed in 2% paraformaldehyde in PBS at 4 °C for 15 min
at 24 h post-transfection with 1 μg each of expression construct. After
thorough rinsing with PBS, the cells were ﬁrst blocked with 10%
normal goat serum and 10% fetal bovine serum diluted in PBS for 30min, and then incubated for 1 h at room temperature with the primary
antibodies, FKRP-STEM (1: 500 dilution) and GM130 (1:500). All
antibodies were diluted in PBS containing 10% fetal bovine serum.
Cells were then incubated with AlexaFluor 594-conjugated anti-
mouse or anti-rabbit secondary antibodies (Gibco/Invitrogen). Im-
munoﬂuorescence was visualized using an Olympus BX51/BX52
ﬂuorescence microscope and images were captured using the
Olympus DP70 Digital Camera System (OPELCO, Dulles, VA).
2.4. Western blot analysis
Transfected cells were harvested 48 h post-transfection. Total
protein of the cell lysate was extracted in 400 μl Triton lysis buffer
containing 1% Triton X-100, 50 mM Tris PH 7.5, 150 mM NaCl, 2 mM
DTT and protease inhibitor cocktail (Sigma-Aldrich). Protein concen-
tration was measured by Bradford protein assay (Bio-Rad Laborato-
ries, Hercules, CA). Equal volume (7.5 μl) of cell lysate (20 μg protein)
and concentrated culture supernatant (250 μl from a total of 2 ml
culture medium) were resolved on a 4–15% linear gradient Tris–HCl
SDS–PAGE gel (Bio-Rad Hercules, CA). The membrane was probed
with primary antibodies followed by horseradish peroxidase-conju-
gated IgG secondary antibodies (Bio-Rad). Western blots were
performed according to the procedure described previously [19]. β-
actin (A5316, Sigma-Aldrich) was used as a control for protein
loading. The signal intensity of the bandswasmeasured by NIH ImageJ
software. Total amount of FKRP in both culture supernatant and cell
lysate of the same culture is considered as 100% and the % of FKRP in
culture supernatant was adjusted by the ratio of total sample volume
(250 μl of culture supernatant:400 μl cell lysate).
2.5. PNGase F deglycosylation
Twenty micrograms of total cell lysate and equal volume of
cultured media were boiled for 10 min in 1× Glycoprotein Denaturing
Buffer (NEB, Ipswich, MA) followed by incubation with 500 units of
PNGase F at 37 °C for 6 h. Samples were analyzed by Western blots as
described earlier.
2.6. Microsome preparation
Cells transfected with FKRP were washed with PBS and homog-
enized in 500 μl of pyrophosphate buffer, pH 7.1 (20 mM sodium
pyrophosphate, 20 mM sodium phosphate monobasic, 1 mM MgCl2,
0.5 mM EDTA and 10% sucrose) with freshly prepared protease
inhibitor cocktail (Roche, Germany). The homogenates were centri-
fuged at 2000 × g for 10 min at 4 °C. Cell pellets were re-homogenized
in same volume of buffer. The supernatants from the two centrifuga-
tions were combined and subjected to ultracentrifugation at 100,000
× g for 1 h at 4 °C. The ﬁnal pellets were dissolved in TX-100 buffer (1%
Triton-100, 50 mM Tris, pH 8, 150 mM NaCl and 0.1% SDS) and
analyzed with the supernatant on SDS–PAGE gel. Culture medium
from FKRP-transfected cells was also ultracentrifugated at 100,000 ×
g for 1 h at 4 °C. Final pellet was dissolved in TX-100 buffer and
analyzed with the supernatant on SDS–PAGE gel.
3. Results
3.1. Normal FKRP is secreted into culture medium
FKRP contains a transmembrane domain and a conserved R/KxxR/K
motif in the N-terminus (Fig. 1). Previous studies have shown that the
arginine at amino acid position 2 (R2) and 5 (R5) immediately adjacent
to the transmembrane domain are critical for Golgi localization [13].
Protein sequence and structureanalysispredict that the transmembrane
domain is a signal peptide (Phobius prediction; phobias.cbr.su.se/cgi-
bin/predict.pl) (Fig. 1). This suggests that FKRP might be secreted. To
Fig. 1. FKRP protein sequence. Asterisks indicate the R2 and R5 amino acids critical for
Golgi localization. Signal peptide sequence predicted by Phobius prediction (phobias.
cbr.su.se/cgi-bin/predict.pl.) is underlined and franked by the bended arrows on top of
the letters. N-glycosylation sites (in box) are predicted by NetNGlyc 1.0 Server (www.
cbs.dtu.dk/services/NetNGlyc/). The predicted cleavage site of the signal peptide is
marked by the arrow between amino acids 27 and 28.(Signal IP 3.0, www.cbs.dtu.dk/
services/SignalIP. Probability, 0.850). The DVD motif is bolded and underlined.
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human FKRP taggedwith a GFP reporter which has beenwidely used as
a tag for tracking the pathway and function of target proteins. OurFig. 2. FKRP secretion in CHO cells. S/N, supernatant from cell culture; C/P, cell pellets; nFKR
cells without vector transfection were used as control. (B) β-actin was used as protein loadin
C/P of the same culture is considered as 100%. (D) Detection of human FKRP/GFP fusion prote
human FKRP in S/N and in C/P from stably transfected CHO cells. (F) Detection of mouse FKR
was used as protein loading control (lower panel). (G) Detection of normal mouse FKRP (mFK
duplicate ofWestern blot was probed with monoclonal antibody JL-8 to YFP (lower panel). YF
in S/N and C/P. Equal volume of 7.5 μl sample was loaded from both S/N and C/P for allWeste
The % of FKRPs has been adjusted by the total volumes of S/N and C/P as described in the M
length FKRP/GFP expressed in the E310X transfected cells.previous study has conﬁrmed that the GFP tag did not alter protein
localization [13-14]. Equal volume of the cultured medium and the cell
lysatewere then analyzed in parallel byWestern blot for thepresence of
FKRP. FKRP proteins were detected as both monomers (∼75 kDa) and
dimers (∼150 kDa) in the cell lysate. FKRP with the expected size of
monomers, but not the dimers were clearly detected in the culture
medium (Fig. 2A). The signal intensity of the FKRP in the culture media
was similar to that (both monomers and dimers) in the cell pellet as
measured by the NIH ImageJ. The amount of FKRP protein in the culture
mediumwas therefore approximately 40% of the total FKRP detected in
both medium and cell pellets after taking the total volume of cell lysate
(250 μl) and culture medium (400 μl) into account (Fig. 2C) (the same
factor will be applied to calculate the % of secreted mutant FKRPs
hereafter). The identity of the FKRP/GFP fusion protein was also
conﬁrmed by antibody to GFP (Fig. 2D). FKRPs were also secreted into
the medium in the cells stably expressing the transgene with similar
percentage (Fig. 2E). Consistent with our previous report [19],
immunohistochemistry showed that normal human FKRP was pre-
dominantly localized within the Golgi apparatus (Fig. 3).
3.2. Missense mutations reduce the levels of FKRP secretion
Previous studies have demonstrated that mutations in FKRP cause
mislocalization of mutant FKRPs to the ER compartment (14, 19). To
determine whether mutations also affect secretion, we examined the
effects of two FKRP mutations, L276I and P448L, which are associatedP, normal human FKRP. (A) Detection of FKRP with antibody FKRP-STEM. Parental CHO
g control. (C) Percentage of FKRP in S/N and C/P. Total amount of FKRP in both S/N and
ins and GFP in S/N and C/P bymonoclonal antibody JL-8 to GFP. (E) Detection of normal
Ps in CHO cells with antibody FKRP-STEM (upper panel). Normal, normal FKRP. β-actin
RP), C318Y and P448Lmutants in CHO cells with antibody FKRP-STEM (upper panel). A
P is predominantly present in the medium of all 3 transfectants. (H) Percentage of FKRP
rn blots. Signal intensity of the bands in theWestern blots wasmeasured by NIH ImageJ.
aterials and methods. Asterisks in A and D indicate the bands corresponding to the full-
Fig. 3. Colocalization of FKRP expression and Golgi marker GM130 by immunohistochemistry. Top panel, control cells without transfection. Middle panel, cells transfected with
normal FKRP expression vector (nFKRP). Bottom panel, cells transfected with E310X expression vector. Left column, cells were stained with antibody to GM130 and detected with
Alexa 594-conjugated goat anti-mouse IgGs (red). Middle column, FKRP expression was detected by antibody FKRP-STEM (green). Right column, GM130 merged with FKRP. Blue,
nuclear staining.
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same culture condition, the levels of mutant FKRP proteins from the
cell pellet were similar to that in the cells expressing normal FKRP
(Fig. 2A). In contrast, the signal intensity of the L276I in the culture
media was only about 22% of that in the cell pellet. The amount of
L276I mutant FKRPs in the medium was therefore approximately 15%
of the total mutant protein. Most signiﬁcantly, the P448Lmutant FKRP
was barely detectable in the culture medium with the proportion
corresponding only 3% of total mutant protein (Fig. 2C). We also
observed that GFP was independently translated, probably utilizing
IRES sequence upstream of the GFP coding region (Fig. 2D). However,
the levels of the GFP in the medium were comparable between the
cells expressing normal FKRP and mutant FKRPs (Fig. 2D). These
results, therefore, indicate that secretion of FKRP is independent to the
level of the expression and secretion of other proteins.
We then examined the secretion of mouse FKRP and the same two
mutants in the CHO cells. Similar pattern of secretion was observed
with the normal FKRP being abundant whereas the mutant P448L
protein was barely detectable in the medium despite high levels of
expression in the cell pellet (Fig. 2F). We also examined the C318Y
mutant, which is associated with severe disease phenotype in WWS
[11]. The mutant protein localized both at the Golgi and ER with
diffuse cytoplasmic signals [19]. Only about 10% of the C318Y protein
was detected in the medium compared to about 24% and 80% of the
P448L mutant and normal mouse FKRPs detected in the media
respectively (Fig. 2G). Thus, secretion is not limited to the human
FKRP and reduction in secretionmay be correlated to disease severity.
3.3. FKRP with a nonsense mutation retains in the Golgi and is secreted
Stable CHO cell lines were created to express the E310X (G928T)
FKRP/GFP. Despite the presence of the nonsense mutation, two
truncated polypeptides with the size of approximately 40 kDa and35 kDa were expressed. Interestingly, only the 35 kDa E310X FKRP was
secreted into themedium,with theproportion accumulatedwithin 48h
reaching levels similar to that detected in themediumof normal human
FKRP (Fig. 2A, C). GFP was only weakly detected in the medium, partly
due to the absence of the kozak sequence in this vector, probably
resulting in decreased level of independent translation (Fig. 2D). The
size difference between the two species of truncated FKRPwas less than
5 kDa. This raised the possibility that the difference was caused by
variations in glycosylation with the smaller form lacking N-glycosyla-
tion. However, PNGaseF digestion showed that the molecular weight of
both truncated FKRPs in the cell pellet aswell as the secreted formwere
reduced by approximately 5 kDa, indicating that both species were
similarly N-glycosylated (Fig. 4A).
Interestingly, a weak band equivalent to the size of full-length FKRP
was also detected in the cell pellets of E310X transfectant by the
antibody to the stem region of the FKRP (asterisk in Fig. 2A). The signal
intensity corresponded to less than 5% of the total truncated FKRP
detected in the cell pellet (Fig. 2C). This band was also detected by the
antibody to GFP, indicating that the 75 kDa band represents the full-
length FKRP/GFP fusion protein (Fig. 2D), probably by the read-through
mechanism.However, full-length FKRP/GFP proteinwas not detected in
the culture medium and this could be due to the limited amount of the
protein within the cells. Immunocytochemistry demonstrated that the
E310X mutant localized to the Golgi in almost all transfected cells
although weak diffused signals within cytoplasm were also present in
some cells (Fig. 3). These results therefore further support that the
presence of GFP tag did not affect FKRP secretion and that alteration in
FKRP transportationwasdependent on speciﬁcmutations of the protein.
3.4. N-terminal signal peptide is cleaved from the secreted FKRP
The size difference of about 5 kDa between the two truncated E310X
FKRP species raises the probability that the smaller species represents
Fig. 4. Deglycosylation of FKRPs with PNGase F digestion. S/N, supernatant from cell
culture; C/P, cell pellets. (A) Human E310X mutant FKRP detected with antibody FKRP-
STEM (upper panel). β-actin is used as protein loading control (lower panel). –, without
PNGase F digestion; +, after PNGaseF digestion. (B) Untagged normal human FKRP
detected with antibody FKRP-STEM (upper panel). β-actin was used as protein loading
control (lower panel).
Fig. 5. Normal FKRP detection in microsome preparations. Fractions of culture medium
(S/N) or cell lysate (C/P) were collected by ultracentrifugation (100,000 × g) and
analyzed by Western blots using antibodies against FKRP (A). Actin (B) was used as a
control for S/N); GM28 (C) and hsp70 (D) were used as controls for C/P. Pellet and
supernatant (Sup) were collected from both culture medium and cell lysate after
ultracentrifugation. Note that the lower band of the cellular FKRP in the pellet of cell
might represent degradation product. The cytoplasmic protein, hsp70, was predom-
inantly found in the supernatant fraction of the cell lysate.
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consistent with the Phobius prediction that the N-terminal peptide
sequence of the FKRP is cleaved at the position between amino acid 27
and 28 (probability, 0.85). The difference in size between the cleaved
and non-cleaved FKRP is estimated to be approximately 3 kDa. Since
SDS–PAGE gel might not be able to distinguish small difference in size
between proteinswithmolecular weight higher than 70 kDa (as shown
in Fig. 2A), we transfected CHO cells with the untagged FKRP and
performed the Western blots using similar amount of FKRP proteins
from both culture medium and cell pellet. The molecular weight of the
wild-type FKRP without the GFP tag was ∼50 kDa and the size of the
secreted FKRP became noticeably smaller than the cellular form in the
pellet. The difference in size between the two species of FKRPs became
more apparent after PNGaseF digestion (Fig. 4B). Similar reduction in
size was observed for both species after digestion with PNGaseF,
indicating that both species contain N-glycosylation (Fig. 4B). Thus, the
reduction in size of the FKRPs is likely the result of cleavage of the signal
peptide, not differential glycosylation.
We also analyzed the presence of FKRPs in different fractions of
cell pellet and culture medium after ultracentrifugation at 100,000 ×
g. Transmembrane proteins will be retained in the pellet because of
the hydrophobicity of the membrane segments and thus, easily
separated from non-transmembrane proteins, which are typically
retained in the supernatant. As shown in Fig. 5, FKRP in culture
medium was present only in the supernatant fraction (lane 2) after
ultracentrifugation, indicating the absence of its N-terminal trans-
membrane domain. In contrast, cellular FKRP together with the Golgi
marker, GM28, were found only in the pellet (Fig. 5, lane 3). The
cellular FKRP was also slightly larger in size compared to the FKRP
secreted in the culture medium. These biochemical features further
support our conclusion that the transmembrane domain was cleaved
from the secreted FKRP, but intact in the cellular FKRP.
4. Discussion
In the present study, we demonstrated that normal FKRP is
secreted into culture medium and mutations can alter the pattern oftransportation. The L276I mutation, often associated with mild
phenotypes in LGMD2I, caused a moderate decrease in secretion
whereas the P448L and C318Y mutations, associated with severe
phenotypes, dramatically reduced the secretion of the mutant
proteins. The underlying mechanism(s) for the altered pattern of
secretion of the mutant FKRPs is not clearly understood. Our previous
studies demonstrated thatnormal FKRPwas transported and targeted to
the Golgi apparatus [13-14,19]. The L276I mutant was also primarily
targeted to theGolgi and less susceptible to proteasomal degradation. In
contrast, the P448L mutant was shown to accumulate in the
endoplasmic reticulum (ER) where it was preferentially degraded in
the proteasome (14). It is therefore possible that ER retention of the
mutantproteins reduces theamountof FKRP secretion. This is consistent
with the fact that the E310X mutant retains in the Golgi and secretes
efﬁciently. However, the levels and size of both L276I and P448Lmutant
proteinswere similar to normal FKRP and no clear degradation products
were demonstrated on Western blots. Furthermore, the C318Y mutant
demonstrated even lower levels of secretion when compared to the
P448L mutant despite the fact that the protein still partially localizes to
the Golgi. Thus, the relationship between secretion and ER retention of
the mutant proteins remains to be elucidated.
Detection of secreted FKRP raises the question whether the N-
terminal hydrophobic domain is cleaved from the FKRP protein. FKRP
has been previously described as a type II transmembrane protein
with its N-terminal a transmembrane domain (N-terminal outside
and C-terminal inside of the ER lumen) (13). Our previous study
showed that the N-terminal 33 amino acids of FKRP are sufﬁcient to
recruit a GFP chimera to the Golgi apparatus. Similar results were
obtained with the N-terminus of fukutin fused to GFP [13]. The
remaining luminal sequence of FKRP fused to GFPwas unable to target
the Golgi apparatus, resulting in diffused distribution within the
cytoplasm. It is therefore suggested that the protein is targeted to the
Golgi apparatus by a non-cleavable signal anchor sequence [13]. Our
results now suggest that the N-terminal signal peptide can be
liberated from the secreted FKRP. However, it remains to be
determined how and when the peptide sequence is cleaved in the
secretory pathway. The observation that normal and E310X FKRPs
both localize predominantly to the Golgi apparatus with the signal
peptide attached makes it plausible that the cleavage may occur after
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proportion of E310X mutant FKRP in the cell pellets has the signal
peptide cleaved whereas cleavage is not apparent for the normal and
other two mutant FKRPs in the cell pellets. This raises the possibility
that different mutations could differentially affect the cleavage of the
signal peptide [20-22].
Mutations in FKRP are associated with muscular dystrophies
ranging from MEB, WWS and MDC1C, with early manifestation and
fatal consequence, to the mild LGMD2I [4,5,9-12]. Asymptomatic
carriers have also been reported [23]. The mechanisms by which
mutations in FKRP cause such wide variations in clinic manifestations
are not clearly understood. Our previous results demonstrated that
FKRP mutants (S221R, A455D, P448L) associated with more severe
clinical phenotypes are generally retained within the ER whereas the
normal FKRP and the L276I mutant are found predominantly in the
Golgi apparatus [13,14]. It was therefore suggested that the degree of
ER retention and preferential degradation by the proteasome might
explain the phenotypic variations among muscular dystrophy
patients with different FKRP mutations [14]. However, Dolatshad et
al. reported that both normal and mutant human FKRPs including
those associated with MDC1C, can be localized to the Golgi. They
suggested that other factors besides mislocalization may also play
important roles in the pathogenesis of the FKRPmutations [24,25]. For
example, FKRP has also been reported in association with the
dystrophin–glycoprotein complex at the sarcolemma, suggesting a
novel function at the muscle membrane [26]. In this study, we
demonstrated that the E310X mutant lacking the entire C-terminal
185 amino acids localized mainly at the Golgi apparatus and is
secreted with comparable efﬁciency to the normal FKRP. Although the
deleted C-terminal sequence contains the putative catalytic DXD
motif, the E310Xmutation together with a L276I mutation is clinically
associated with mild LGMD2I (case unreported). These results
together clearly demonstrate the complexity of the effects of FKRP
mutations on the localization, secretion and function of the protein.
In summary, our results conﬁrmed that FKRP is an N-glycosylated
protein and demonstrated that FKRP is secreted with the signal
sequence apparently cleaved. Mutations alter the pattern of secretion.
Alteration of the secretion pathway and translation by individual
mutation may also partly account for the wide variations in clinic
phenotypes associated with FKRP-related diseases.
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